Thomas C. Corbridge

Challenges in Evaluating Clinical Remission in Severe Asthma: Insights from the Mayo Clinic

Kaiser G. Lim, Arijita Deb, Thomas C. Corbridge, Lydia Lee et autres

INTRODUCTION: Clinical remission (CR) is an ambitious and achievable treatment goal for many patients with severe asthma. This study evaluated real-life care of patients in the U.S. using CR criteria defined by the American Thoracic Society; American College of Allergy, Asthma, and …

us (code pays fourni par la source)

Benefit of Early Versus Delayed Intervention With Mepolizumab in Patients With Severe Uncontrolled Asthma (SUA): A Retrospective Cohort Study

Thomas C. Corbridge, Guillaume Germain, Susannah Ripley, François Laliberté et autres

us (code pays fourni par la source)

Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis

Wendy C. Moore, Alexandra Stach-Klysh, Thomas C. Corbridge, Elizabeth Packnett et autres

Objective Although the efficacy of mepolizumab in reducing exacerbations and oral corticosteroid (OCS) use in severe asthma is well-established, real-world long-term effectiveness data are limited. This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year …

us (code pays fourni par la source)

Eosinophil count testing in patients with asthma varies by healthcare provider type in the US: a retrospective study

Sameer K. Mathur, Thomas C. Corbridge, Elizabeth Packnett, Krutika Jariwala‐Parikh et autres

BACKGROUND: Patients with asthma with an eosinophilic phenotype may be eligible for additional treatment options to improve disease control; however, the prevalence and frequency of eosinophil testing is unknown. This study assessed blood eosinophil count testing prevalence in patients with asthma by …

us (code pays fourni par la source)

IMPACT OF MEPOLIZUMAB ON INHALED CORTICOSTEROIDS (ICS), SHORT-ACTING BETA-AGONISTS (SABA) AND ORAL CORTICOSTEROIDS (OCS) USE IN SEVERE ASTHMA: A RETROSPECTIVE REAL-WORLD STUDY

Jared Silver, Arijita Deb, LYDIA LEE, Louise Yu et autres

Real-World Impact of Mepolizumab on Pediatric and Adolescent Patients With Severe Asthma in the United States

Thomas C. Corbridge, Malena Mahendran, Annalise Hilts, Kai Zhang et autres

us (code pays fourni par la source)

Evaluation of Clinical Remission Indicators in Asthma Patients Treated With Biologics in a Real-world Setting

Kaiser G. Lim, Thomas C. Corbridge, L. Lee, Hannah Barman et autres

us (code pays fourni par la source)

Influence of Different Thresholds for Asthma Control on Clinical Remission Composite Outcome in Patients Uncontrolled on ICS/LABA: A Post-hoc Analysis of Single Inhaler Triple Therapy With FF/UMEC/VI in the CAPTAIN Trial

John J Oppenheimer, Ian Douglas Pavord, Jodie Crawford, Thomas C. Corbridge et autres

us, gb (code pays fourni par la source)

Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma

Thomas B. Casale, Thomas C. Corbridge, Guillaume Germain, François Laliberté et autres

BACKGROUND: Systemic corticosteroid (SCS) use remains widespread among patients with severe asthma, despite associated complications. OBJECTIVE: Evaluate the association between cumulative SCS exposure and SCS-related complications in severe asthma. METHODS: This retrospective, longitudinal study used claims data from the Optum Clinformatics Data …

us, ca (code pays fourni par la source)

Targeting Asthma Remission as the Next Therapeutic Step Toward Improving Disease Control

William W. Busse, Geoffrey Lowell Chupp, Thomas C. Corbridge, Alexandra Stach-Klysh et autres

The long-term goal of asthma management is to achieve disease control, comprising the assessment of 2 main domains: (1) symptom control and (2) future risk of adverse outcomes. Decades of progress in asthma management have correlated with increasingly ambitious disease control targets. …

us (code pays fourni par la source)

Effectiveness of Switching to Mepolizumab from Other Biologics in Asthma Patients: A Real-World Analysis

Thomas C. Corbridge, Alexandra Stach-Klysh, François Laliberté, Annalise Hilts et autres

us (code pays fourni par la source)

Impact réel du switch d’autres biologiques vers mépolizumab chez les patients asthmatiques sévères

A. Deb, Chi Gao, Thomas C. Corbridge, Alexandra Stach-Klysh et autres

us, ca (code pays fourni par la source)